cannabis
This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.
Loading study record…
Loading study record…
A cross-sectional and retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. All patients who admitted at PMNIDAT from October 2013 to September 2019 were included. Patients aged 18-65 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP and Had a positive urine test of cannabis were included. Cannabis use is a component cause of psychosis.More than half of symptoms of cannabis-induced psychosis (CIP) were hallucination, delusion, irritable and anxiety. Antipsychotic drug was still a key psychotropic drugs for treatment of CIP. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychotics
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2021-06-30
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Research network
Interventions
This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.
Eligibility
Medical chart which diagnosis by ICD-10 with cannabis-induced psychosis who admitted at PMNIDAT from October 2013 to September 2019 at Princess Mother National Institute on Drug Abuse Treatment.
primary outcomes
Time frame: 30 days
Pharmacological treatment pattern for cannabis-induced psychosis during admission
secondary outcomes
Time frame: Day1, Day 8, Day 15 and Day 22
A high BPRS score is more severe of symptoms than a lower score
Publications